Hydrocortison Acis (Hydrocortisone)

Hydrocortison Acis is prescribed for several conditions that require glucocorticoid therapy. It is used under medical supervision to manage hormonal deficiencies and inflammatory disorders.

• Replacement therapy in adrenal insufficiency
• Treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis
• Management of severe allergic reactions
• Adjunct therapy for certain dermatologic conditions when systemic treatment is needed
• Supportive care in certain endocrine disorders

• Hydrocortison Acis delivers hydrocortisone, which binds to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus and modulates gene transcription, leading to decreased production of pro‑inflammatory cytokines, inhibition of leukocyte migration, and suppression of immune responses. These actions collectively produce anti‑inflammatory and immunosuppressive effects throughout the body.

Adverse reactions to oral hydrocortisone can vary in frequency and severity.

Common

• Increased appetite and weight gain
• Mild gastrointestinal discomfort
• Transient mood changes such as irritability
• Fluid retention causing mild swelling

Serious

• Signs of infection that do not improve
• Uncontrolled high blood pressure
• Severe electrolyte disturbances, such as low potassium
• Signs of adrenal suppression after abrupt discontinuation

Patients should be evaluated for potential risks before starting Hydrocortison Acis, and ongoing monitoring is recommended during therapy.

• Assess for active infections or tuberculosis before initiation
• Monitor blood pressure, blood glucose, and electrolyte levels regularly
• Use the lowest effective dose for the shortest duration possible
• Caution in patients with a history of peptic ulcer disease or osteoporosis
• Discuss pregnancy, breastfeeding, and fertility considerations with a healthcare professional
• Avoid abrupt discontinuation to prevent adrenal crisis

Hydrocortison Acis may interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use of strong CYP3A4 inducers such as rifampin, which may reduce hydrocortisone levels
• High‑dose non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase gastrointestinal bleeding risk
• Live vaccines, as immunosuppression can diminish vaccine effectiveness

Use with caution

• Anticoagulants, because glucocorticoids may enhance anticoagulant effects
• Diuretics, which can exacerbate electrolyte imbalances
• Antidiabetic agents, as hydrocortisone may raise blood glucose levels